These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31816249)

  • 1. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
    Brandes JL; Diener HC; Dolezil D; Freeman MC; McAllister PJ; Winner P; Klatt J; Cheng S; Zhang F; Wen S; Ritter S; Lenz RA; Mikol DD
    Cephalalgia; 2020 Jan; 40(1):28-38. PubMed ID: 31816249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
    Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
    Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
    J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
    Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing and durability of response to erenumab in patients with chronic migraine.
    Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
    Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
    Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
    Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
    Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
    Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Lipton RB; Dodick DW; Kudrow D; Reuter U; Tenenbaum N; Zhang F; Lima GPDS; Chou DE; Mikol DD
    Cephalalgia; 2021 Dec; 41(14):1458-1466. PubMed ID: 34407654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
    Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
    J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
    Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
    Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
    Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
    Hirata K; Sakai F; Takeshima T; Imai N; Matsumori Y; Yoshida R; Numachi Y; Peng C; Mikol DD; Cheng S
    J Headache Pain; 2021 Sep; 22(1):110. PubMed ID: 34537006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
    Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.